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Abstract: 
Objective: 
Pathological changes within the hypothalamus have been proposed to mediate circadian 
rhythm and habitual sleep disturbances in individuals with Huntington’s disease (HD). 
However, investigations examining the relationships between hypothalamic volume and 
circadian rhythm and habitual sleep in individuals with HD are sparse. This study aimed to 
comprehensively evaluate the relationships between hypothalamic pathology and circadian 
rhythm and habitual sleep disturbances in individuals with premanifest HD. 
Methods: 
Thirty-two individuals with premanifest HD and twenty-nine healthy age- and gender-
matched controls participated in this dual-site, cross-sectional study. Magnetic resonance 
imaging scans were performed to evaluate hypothalamic volume. Circadian rhythm and 
habitual sleep were assessed via measurement of morning and evening cortisol and melatonin 
levels, wrist-worn actigraphy, the Consensus Sleep Diary and sleep questionnaires. 
Information on mood, physical activity levels and body composition were also collected. 
Results: 
Compared to healthy controls, individuals with premanifest HD displayed significantly 
reduced grey matter volume in the hypothalamus, decreased habitual sleep efficiency and 
increased awakenings; however, no alterations in morning cortisol or evening melatonin 
release were noted in individuals with premanifest HD. While differences in the associations 
between hypothalamic volume and cortisol and melatonin output existed in individuals with 
premanifest HD compared to healthy controls, no consistent associations were observed 
between hypothalamic volume and circadian rhythm or habitual sleep outcomes.  
Conclusion: 
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While significant differences in associations between hypothalamic volume and cortisol and 
melatonin existed between individuals with premanifest HD and healthy controls, no 
differences in circadian markers were observed between the groups. This suggests that 
circadian regulation is maintained despite hypothalamic pathology, perhaps via neural 
compensation. Longitudinal studies are required to further understand the relationships 
between the hypothalamus and circadian rhythm and habitual sleep disturbances in HD as the 
disease course lengthens. 
 
Keywords:  
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1. Introduction 
Circadian rhythm and habitual sleep disturbances are common features of Huntington’s 
disease (HD) that occur early in the disease course and exacerbate impairments in cognitive 
function, metabolism, hormone regulation, mood and quality of life (Aziz et al., 2010; 
Briançon-Marjollet et al., 2015; Lazar et al., 2015; Morton et al., 2005). 
A number of studies have reported dysregulation of markers of circadian rhythm and habitual 
sleep-wake outcomes in individuals with HD. In particular, increased morning cortisol output 
has been reported in individuals with premanifest HD (Hubers et al., 2015; van Duijn et al., 
2010). Reduced mean and acrophase concentrations and a temporal spread of melatonin 
release, indicating a potential phase shift in melatonin, have been reported in individuals with 
premanifest HD (Kalliolia et al., 2014). Furthermore, studies have reported disruption of the 
sleep-wake cycle and delayed sleep phase in individuals with HD (Aziz et al., 2010; Morton 
et al., 2005). Despite these findings, the neurobiological origin of circadian rhythm and 
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habitual sleep-wake disturbances in individuals with HD has been poorly investigated and 
warrants further exploration. 
Pathological changes within the hypothalamus have been proposed to disrupt circadian 
rhythm and sleep in individuals with HD (Aziz et al., 2010; Morton et al., 2005). 
Hypothalamic nuclei, particularly the suprachiasmatic nucleus, are known to be integrally 
involved in the regulation of circadian markers such cortisol and melatonin, as well as sleep 
(Saper et al., 2005; Steiger, 2002). Studies have reported grey matter volume loss and 
microglial activation within the hypothalamus and circadian rhythm and sleep disturbances 
that arise concomitantly in individuals with premanifest HD (Lazar et al., 2015; Morton et al., 
2005; Politis et al., 2008; Soneson et al., 2010). Despite these findings, only one study has 
examined the potential link between neural pathology and circadian rhythm and sleep 
disturbances in individuals with HD (Baker et al., 2016). Baker et al (2016) reported an 
association between subjective sleep disturbances and neural pathology in HD. However, the 
authors did not use formalised sleep questionnaires to examine sleep and did not evaluate 
markers of circadian rhythm relative to neural pathology. There is, therefore, a need for 
subsequent research to investigate more closely the potential relationships between 
hypothalamic pathology and circadian rhythm and sleep disturbances in HD. 
The purpose of this study was to evaluate whether hypothalamic pathology is associated with 
the dysregulation of biological and clinical markers of circadian rhythm, particularly cortisol, 
melatonin and sleep-wake timing, and habitual sleep in individuals with premanifest HD. We 
hypothesized that hypothalamic pathology would be associated with dysregulation of 
circadian rhythm and habitual sleep, as evidenced by significant alterations in cortisol and 
melatonin release and habitual sleep-wake cycles in individuals with premanifest HD. 
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2. Materials and Methods 
2.1 Participants 
Thirty-five premanifest HD individuals and 31 age- and gender-matched healthy controls 
were recruited from existing databases, HD clinics and media advertisements in Perth and 
Melbourne. Inclusion criteria for premanifest HD individuals were a cytosine-adenine-
guanine (CAG) repeat length ≥ 40 and a diagnostic confidence score < 2 on the Unified 
Huntington’s Disease Rating Scale Total Motor Score (UHDRS-TMS) (Reilmann et al., 
2014). Exclusion criteria for all participants were, presence of known musculoskeletal, 
metabolic, endocrine, cardiovascular or sleep disorders, recent or long-standing substance 
abuse, shift work other neurological conditions and, for healthy controls, a family history of 
HD. Five participants withdrew from the study or contributed incomplete data and were 
excluded from analyses, leading to a total of 32 premanifest HD and 29 healthy individuals. 
All aspects of the study were conducted in accordance with the Declaration of Helsinki. 
Ethical approval was granted by the Edith Cowan University and Monash University Human 
Research Ethics Committees. All participants provided written informed consent. 
2.2 Study Procedures 
Testing procedures included 3T MRI scans for hypothalamic imaging, saliva sampling to 
quantify morning cortisol and evening melatonin, wrist-worn actigraphy for monitoring sleep, 
a sleep diary for monitoring habitual sleep patterns and questionnaires for monitoring sleep 
quality, psychological stress, physical activity, anxiety and depression. 
2.3 Acquisition and Pre-Processing of MRI Data 
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T1-weighted structural images of the brain were obtained from each participant in Perth or 
Melbourne using a GE Healthcare Discovery and a Siemens Skyra 3T MRI scanner, 
respectively. In Perth, images were acquired with a 24-channel head coil using an IR-SPGR 
sequence (TA = 9 m 59 s, TR = 3 s, TE = Min, TI = 400 ms, flip angle = 11˚, field of view = 
256 mm, image matrix = 256 x 256, 1 mm
3
 isotropic voxels). In Melbourne, acquisition took 
place with a 32-channel head coil and an MP-RAGE sequence (TA = 9 m 14 s, TR = 2.3 s, 
TE = 2.96 ms, TI = 900 ms, flip angle = 9˚, field of view = 256 mm, image matrix = 256 x 
256). Images were acquired consistently across both sites according to the Alzheimer’s 
Disease Neuroimaging Initiative protocols for multi-site imaging (Jack et al., 2008). Pre-
processing of images was conducted according to the SPM12 pipeline (supplementary data). 
2.4 Measurement of Biological Markers of Circadian Rhythm 
Salivary cortisol and melatonin have previously been shown to be useful measures of 
circadian rhythm (Dickmeis, 2009; Voultsios et al., 1997). Participants were given written 
and verbal instructions to collect saliva samples by passive drool into polypropylene 
collection tubes (SSI Bio) at the same time on two consecutive days for determination of 
morning cortisol and evening melatonin concentrations. Participants collected saliva samples 
at four time points in the morning (15, 30, 45 and 60 minutes following awakening) for 
morning cortisol analysis and four time points in the evening at one hour intervals from two 
hours before their usual bedtime (T1) until one hour after their usual bedtime (T4) for 
melatonin analysis. Saliva samples were collected according to criteria from previous studies 
(van Duijn et al., 2010; Voultsios et al., 1997) to avoid contamination of samples (see 
supplementary files). Based on these criteria, a questionnaire was devised to monitor 
participant compliance. Saliva samples were stored at -80˚C until analysis using 
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commercially available salivary cortisol and melatonin ELISA kits (Salimetrics, USA) 
according to the manufacturer’s instructions. 
2.5 Measures of Habitual Sleep-Wake Parameters 
2.5.1 Actigraphy 
At the commencement of the study, a convenience sample of individuals with premanifest 
HD and healthy controls were given the opportunity to undertake habitual sleep monitoring 
using actigraphy. Of the original cohort, 19 premanifest HD and 24 healthy individuals 
underwent home-based actigraphy sleep measurement for seven consecutive nights to assess 
habitual sleep-wake patterns. Actigraphy was recorded at 30 Hz using wrist-worn GT3X+ 
ActiGraph monitors (ActiGraph, USA) on the non-dominant wrist. The start and end time of 
sleep periods were recorded using the Consensus Sleep Diary (Carney et al., 2012). 
Wrist-based actigraphy has been used previously to assess circadian rhythm via analysis of 
habitual sleep-wake patterns in individuals with HD and in other populations (Ancoli-Israel et 
al., 2003; Morton et al., 2005). Therefore, here we similarly used ActiGraph monitors, which 
were initialised, downloaded and analysed using the ActiLife software (version 6.8). Data 
were scored with a low frequency extension filter in 60 second epochs as awake or sleep 
according to the Cole-Kripke algorithm (Cole et al., 1992). Total sleep time, sleep onset 
latency, wake after sleep onset, number of awakenings and sleep efficiency outcomes were 
calculated for each night and then averaged across the seven nights to obtain single values for 
use in subsequent analyses.  
2.5.2 Consensus Sleep Diary 
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Habitual sleep-wake timing was evaluated using the Consensus Sleep Diary (Carney et al., 
2012). Participants were required to document time in bed, time of awakening, time to sleep 
onset, number of awakenings and sleep quality for seven nights in combination with 
actigraphy assessment. 
2.5.3 Subjective Sleep Quality and Daytime Somnolence 
Sleep quality was assessed in all participants using the Pittsburgh Sleep Quality Index (PSQI) 
(Buysse et al., 1989). Daytime somnolence was measured using the Epworth Sleepiness Scale 
(ESS) (Johns, 1991). 
2.6 Stress, Anxiety and Depression Symptomatology 
The Perceived Stress Scale (Cohen et al., 1983) was used to measure psychological stress in 
the previous month. The Perceived Stress Scale has been demonstrated to be a valid measure 
of perceived psychological stress in individuals with HD (Downing et al., 2011). Symptoms 
of anxiety and depression were measured using the Hospital Anxiety and Depression Scale 
(HADS). This scale has been previously demonstrated to be valid and reliable in HD (De 
Souza et al., 2010). 
2.7 Physical Activity 
Physical activity levels were recorded prior to and during saliva sampling days using the 
Minnesota Leisure Time Physical Activity Questionnaire. Metabolic equivalents (METs) 
were calculated using recorded physical activity levels, the Compendium of Physical 
Activities database and estimated resting metabolic rate (RMR) (Ainsworth et al., 2011). 
RMR was calculated using the Harris-Benedict formula (see supplementary file) (Harris and 
Benedict, 1918). 
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2.8 Statistical Analysis 
2.8.1 Hypothalamic Volume 
A hypothalamus mask from the WFU Pick Atlas (http://fmri.wfubmc.edu/software/pickatlas), 
dilated by 3mm, was used to restrict analysis to this area (Breen et al., 2016). Grey matter 
images from individuals with premanifest HD and healthy controls were compared voxel-
wise using a two-sample t-test to evaluate group differences in the hypothalamus. Gender, 
site and age were included as covariates of no interest. Next, we investigated group 
differences in the association between hypothalamic volume and cortisol and/or melatonin 
output in individuals with premanifest HD compared to healthy controls, using a categorical 
by continuous covariate interaction model. The model included group regressors, one for 
each group, and regressors modelling change in cortisol or melatonin output, one for each 
group. The following contrasts were used to model the group by cortisol/melatonin output 
interaction effect: [0 0 1 -1] and [0 0 -1 1]. Gender, site, age, PSS, ESS, and PSQI were 
included as covariates of no interest. In premanifest HD, we adjusted also for CAP score.  
We also evaluated the relationship between hypothalamic volume and disease status (i.e. 
CAP score). Given the exploratory nature of this study and our a priori interest in the 
hypothalamus, the threshold for statistical significance for all analyses was set at α = 0.05. 
2.8.2 Salivary Cortisol and Melatonin 
Missing data points from saliva sampling (removed due to suspected blood contamination) 
were imputed by calculating the average of the participant’s previous and subsequent values 
in the curve (n= 2 of 504, 0.40%), unless the missing value was the first time point in each 
curve (n= 3 of 504, 0.60%), in which case the group average was imputed to avoid removing 
the participant from analyses and maintain sample size (van Duijn et al., 2010). Area under 
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the curve with respect to ground (AUCG) was calculated using the trapezoid rule for morning 
cortisol and evening melatonin output on the two consecutive days (Dijk et al., 2012; van 
Duijn et al., 2010).  
Normality assumptions for all variables were tested using a Shapiro-Wilk test. Between-
group differences were examined using a t-test for continuous variables and a two sample 
proportion test for categorical variables. Spearman correlation coefficient was calculated to 
assess relationships between cortisol AUCG, melatonin AUCG and Perceived Stress Scale, 
PSQI and Consensus Sleep Diary scores. Statistical significance was set at p ≤ 0.05. 
Statistical analyses were performed using STATA version 9.1. 
 
3. Results 
3.1 Participant Demographics and Clinical Characteristics 
There were no significant differences for age or gender between premanifest HD patients and 
healthy controls (p = 0.472 and 0.283, respectively; Table 1). 
3.2 Hypothalamic Volume 
A significant decrease in grey matter volume in the anterior-superior region of the left side of 
the hypothalamus was observed in individuals with premanifest HD compared to healthy 
controls (peak voxel at MNI -9 1 -4; t = 2.38; k = 22; see Figure 1A). We also found a 
significant negative association in premanifest HD between grey matter volume bilaterally in 
the anterior-superior and anterior-inferior regions of the hypothalamus and CAP score (r = -
0.42; see Table 3 and Figure 1B). 
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3.3 Biological Markers of Circadian Rhythm 
No significant differences were observed between individuals with premanifest HD and 
healthy control participants in the amplitude of morning cortisol or evening melatonin output 
at any of the time points sampled (p > 0.05; Table 2). Furthermore, no differences were 
observed in total morning cortisol (p = 0.357) or evening melatonin (p = 0.219) output when 
subject to area under the curve analysis with respect to ground (AUCG; Table 2). 
 
3.4 Habitual Sleep Outcomes 
3.4.1 Actigraphy 
Premanifest HD individuals exhibited a decreased sleep efficiency compared to healthy 
controls (p = 0.012). A significant increase in the number of awakenings (p = 0.039) and time 
spent awake after sleep onset (p = 0.028) were also observed in premanifest HD participants 
compared to healthy controls (Table 2). 
3.4.2 Consensus Sleep Diary 
No significant differences were observed in self-report sleep outcomes using the Consensus 
Sleep Diary (Table 2). 
3.4.3 Subjective Sleep Outcomes 
There were no significant differences between premanifest HD individuals and healthy 
controls in global PSQI score (p = 0.134). The average PSQI score in the premanifest HD 
group fell above the cut-off of 5, suggesting a disruption in sleep quality. Although healthy 
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controls scored significantly higher than premanifest HD individuals on the ESS, scores for 
both groups remained within the normative range (< 10) (Johns, 1991).  
3.5 Stress, Anxiety and Depression Questionnaires 
No significant differences were observed in stress (p = 0.062), anxiety (p = 0.164) or 
depression (p = 0.427) symptomatology between premanifest HD and healthy individuals 
(Table 2). Furthermore, values on the Perceived Stress Scale and HADS were considered 
below threshold, indicating no clinically meaningful stress, anxiety or depressive 
symptomatology in the premanifest HD and healthy control groups. 
3.6 Physical Activity 
The premanifest HD group reported significantly less monthly physical activity (METs) than 
healthy controls (p = 0.022; Table 1). Physical activity on the day prior to saliva sampling did 
not differ between the groups, negating any acute effects of physical activity on hormone 
levels. Furthermore, there was no association between reported physical activity levels and 
measures of sleep, cortisol and melatonin output and hypothalamic volume. 
3.7 Associations Between Hypothalamic Volume and Circadian Markers  
A significant negative association was revealed by voxel-wise analysis between grey matter 
volume in the left hypothalamus and morning cortisol output in the premanifest HD group. 
This association was found to be moderate (r = -0.39), indicating that lesser grey matter 
volume in the left side of the hypothalamus is associated with greater morning cortisol 
output. No significant association was observed in the healthy control group (Figure 1E and 
Table 3). This group difference in the association between hypothalamic volume and morning 
cortisol output was statistically significant, as shown by interaction analysis (Figure 1C, 
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Figure 1E and Table 3). The group by cortisol output interaction encompassed two separate 
areas – first, the region spanning the posterior hypothalamus and the superior tuberal 
hypothalamus and second, the anterior-inferior hypothalamic region. 
A negative relationship between grey matter volume in the right side of the hypothalamus and 
morning cortisol output was seen in healthy controls, but not in premanifest HD participants, 
and the group by cortisol output interaction was significant (Table 3). However, the 
association between right hypothalamic grey matter volume and morning cortisol output in 
healthy controls was weak (r = -0.06), indicating a non-existent relationship in this case. 
Grey matter volume in the left side of the hypothalamus was positively associated with 
evening melatonin output in healthy controls (r = 0.36), but not in premanifest HD 
individuals (Figure 1F and Table 3). This group difference in the correlation between 
hypothalamic volume and evening melatonin output was statistically significant (Figure 1D, 
Figure 1F and Table 3). The group by melatonin output interaction encompassed the region 
extending from the superior tuberal hypothalamus to the anterior-inferior hypothalamus.  
3.8 Associations Between Hypothalamic Volume and Habitual Sleep Outcomes 
No reliable pattern of associations was observed between hypothalamic volume and measures 
of subjective sleep quality, sleep onset latency, number of awakenings, sleep efficiency or 
perceived stress in the premanifest HD or healthy cohorts. 
 
4. Discussion 
Hypothalamic pathology and disturbances in circadian rhythm and sleep arise during the 
premanifest stages of HD. Despite the central role of the hypothalamus in mediating the 
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circadian rhythm and sleep-wake timing, only one study has attempted to discern the possible 
relationship between hypothalamic pathology and sleep disturbances in individuals with HD 
(Baker et al., 2016). In the absence of robust data, the aim of this study was to examine the 
potential relationship between hypothalamic pathology and circadian rhythm and habitual 
sleep outcomes in individuals with premanifest HD. 
Consistent with previous findings (Soneson et al., 2010), significantly reduced grey matter 
volume was observed in the hypothalamus of individuals with premanifest HD compared to 
healthy controls. Using normative parcellations of the hypothalamus that rely on visible 
anatomic landmarks in MR images (Makris et al., 2013), this reduced grey matter volume can 
be located to the anterior-superior region of the hypothalamus, a region comprising the 
paraventricular nucleus (PVN), which mediates the release of cortisol and melatonin. 
Reduced hypothalamic volume was found to be associated with CAP score, suggesting a 
relationship between estimated time to disease onset and loss of hypothalamic grey matter 
volume. Interestingly, degeneration within the hypothalamus was leftward biased. The reason 
for this is unknown. Studies have reported a leftward-biased pattern of grey matter atrophy in 
the striatum in individuals with manifest HD (Minkova et al., 2018; Mühlau et al., 2007), 
however, this has not been reported in the striatum or the hypothalamus in individuals with 
premanifest HD. Minkova et al. (2018) postulated that the earliest pathological changes in the 
hypothalamus occur on the left side and become more apparent as individuals approach 
clinical onset, however additional research is needed to support this supposition.  
The pathological mechanisms responsible for reduced hypothalamic volume in individuals 
with HD are not yet understood. Evidence from post-mortem investigations and studies in 
mouse models provides insight into potential mechanisms by which hypothalamic changes 
could occur, as well as mechanisms by which these changes could impact on circadian 
rhythm and habitual sleep outcomes. For example, neuronal inclusions of mutant huntingtin 
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in suprachiasmatic nucleus (SCN) tissue at post-mortem (Aziz et al., 2008), may directly 
mediate changes in the functioning of the SCN. Such neuronal inclusions of mutant 
huntingtin within the SCN could reduce the number of vasoactive intestinal polypeptide and 
arginine vasopressin expressing neurons, which are crucial in the regulation of SCN activity 
(Aton et al., 2005; Hofman and Swaab, 1994), as well as post-transcriptional changes in these 
neuropeptides, which have been reported in HD (van Wamelen et al., 2013). These changes, 
together with a loss of orexin-releasing neurons in the lateral hypothalamus which has been 
reported in individuals with HD at post-mortem and in mouse models of HD (Aziz et al., 
2008; Petersén et al., 2005), could result in impaired functioning of the hypothalamic nuclei 
and lead to the disruption of the circadian rhythm and sleep-wake cycle that has been 
reported in individuals with HD and in HD mouse models (Kudo et al., 2011; Loh et al., 
2013; Morton, 2013; Morton et al., 2005). These potential mechanisms are complex and 
interrelated and require further investigation. 
The reduction in hypothalamic grey matter volume in individuals with premanifest HD was 
significantly associated with morning cortisol release. This relationship was not observed in 
healthy controls. Conversely, the association between hypothalamic volume and evening 
melatonin concentrations observed in healthy controls was absent in individuals with 
premanifest HD. Both the group by cortisol output and the group by melatonin output 
interaction effect on hypothalamic grey matter volume occurred across regions encompassing 
the SCN and the PVN. Despite significantly reduced habitual sleep efficiency and an increase 
in the number of awakenings and time spent awake after sleep onset in individuals with 
premanifest HD, which aligns with previous reports of sleep disturbances in premanifest HD 
(Lazar et al., 2015), hypothalamic volume was not significantly associated with habitual sleep 
outcomes. The lack of consistent associations between hypothalamic volume and habitual 
sleep outcomes was unexpected, especially considering the known role of the hypothalamus 
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in regulating the sleep-wake cycle via the SCN and its connections with the ventrolateral 
preoptic nucleus and the lateral area within the hypothalamus (Bartlett et al., 2016; Saper et 
al., 2005).  
While inconsistent relationships were observed between hypothalamic volume and habitual 
sleep outcomes, further studies should assess the impact of reduced hypothalamic volume on 
changes in the underlying sleep electroencephalogram, which is reported to be altered in HD 
mouse models and in individuals with HD (Fisher et al., 2013; Fisher et al., 2016; Kantor et 
al., 2013; Lazar et al., 2015; Piano et al., 2017). Such analyses would allow further 
characterisation of the impact of hypothalamic changes on sleep outcomes in HD.  
Despite observing differences in the relationships between hypothalamic grey matter volume 
and cortisol and melatonin in the premanifest HD cohort compared to healthy controls, no 
differences in morning cortisol or evening melatonin release were observed between the two 
groups, which is contradictory to previous reports (Kalliolia et al., 2014; van Duijn et al., 
2010). It is important to note that a large proportion of our premanifest HD cohort were 
females (65.6%). This is of relevance as sex-specific differences in circadian rhythm 
dysfunction have been reported in HD mouse models (Kuljis et al., 2016). In particular, 
female HD mice exhibit less severe or delayed changes in activity levels and behavioural 
fragmentation compared to male HD mice (Kuljis et al., 2016). Therefore, the lack of 
differences in cortisol and melatonin release between individuals with premanifest HD and 
healthy controls may be related to sex-specific effects.  
Conceivably, the right side of the hypothalamus, or indeed other structures involved in the 
release of cortisol and melatonin, such as the pituitary or pineal glands, may be able to 
compensate for the reduced hypothalamic volume during the premanifest stages of the 
disease and thereby maintain normal regulation of cortisol and melatonin release. This is 
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supported by emerging evidence indicating the presence of compensatory neural functions in 
individuals with HD (Gregory et al., 2017; Scheller et al., 2014). This theory nevertheless 
requires further validation in larger longitudinal studies.  
This study is not without limitations. Firstly, current imaging methods are not yet sensitive 
enough to capture the individual nuclei within the hypothalamus; however, parcellation 
approaches that rely on anatomic landmarks visible on MR images (e.g. Makris et al., 2013) 
allow the distinction of the different hypothalamic regions, which affords some insight into 
which structures may be affected. Secondly, this study evaluated cortisol and melatonin 
regulation using saliva sampling, which is known to be more variable than blood sampling. 
However, salivary cortisol and melatonin sampling was preferred to blood sampling as 
previous studies indicate that blood sampling elevates cortisol levels (Weckesser et al., 2014). 
Thirdly, this study included a large proportion of females with HD, which may have 
influenced our ability to find significant differences in cortisol/melatonin release between 
individuals with premanifest HD and healthy controls. Discrepancies in cortisol and 
melatonin findings between this study and others may also reflect differences in measurement 
protocols (i.e., frequency of sampling time points), patient characteristics or seasonal 
differences (Kalliolia et al., 2014; Stothard et al., 2017; van Duijn et al., 2010). A lack of 
concordance also existed between the habitual sleep measures, potentially due to differences 
in reporting methods (i.e. subjective versus objective). No evidence of elevated stress, anxiety 
or depression was noted, indicating that mood disorders did not impact on markers of 
circadian rhythm or habitual sleep. Future studies should assess the relationship between 
hypothalamic pathology and sleep architecture in individuals with premanifest HD using 
polysomnography. 
In summary, our findings show that individuals with premanifest HD exhibit leftward biased 
hypothalamic pathology that is differentially associated with markers of circadian rhythm, but 
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not consistently associated with habitual sleep-wake deficits, when compared to healthy 
controls. However, the lack of differences in concentrations of markers of circadian rhythm 
between the two groups suggests the possibility of neural compensation, facilitated by the 
right hemisphere of the hypothalamus or by other brain structures involved in the circadian 
and sleep cycles, as a mechanism involved in maintaining the regulation of the circadian 
rhythm and habitual sleep-wake function in individuals with premanifest HD. Larger, 
longitudinal studies are required to further investigate the role of hypothalamic pathology in 
circadian rhythm and habitual sleep-wake disturbances in HD as the disease course lengthens. 
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Figure 1. Results from voxel-based morphometry analyses showing overlap between maps of 
(A) the hypothalamic volume group difference, (B) association between hypothalamus loss 
and CAPs in premanifest HD, (C) group by cortisol output interaction and (D) group by 
melatonin output interaction. (E) shows the map of group by cortisol output interaction effect 
on hypothalamic volume (as per voxel-wise analysis) and a scatterplot illustrating the 
interaction and (F) shows the map of group by melatonin output interaction effect on 
24 
 
hypothalamic grey matter volume and scatterplot illustrating the interaction. The data points 
in the scatterplot correspond to the average intensity across all voxels within the area 
exhibiting a significant interaction effect for each participant. Slice labels are displayed on 
top. Cross-slices are shown. Crosshairs in (A), (B), (C), and (D) are centred at MNI -9 1 -5. 
L= left; R= right. 
 
Table 1. Demographic and clinical characteristics of premanifest Huntington’s disease and 
healthy control participants.  
 Premanifest HD 
(n=32) 
Healthy 
Controls (n=29) 
p-value 
Demographic Characteristics 
     Age, mean ± SD 44.5 ± 11.4 44.3 ± 10.8 0.472 
     Male, n (%) 11 (34.4) 8 (27.6) 0.283 
Clinical Characteristics 
     CAGn, mean ± SD 42.8 ± 2.8 N/A N/A 
     Estimated age of onset, median (IQR) 47.4 (44.9-55.7) N/A N/A 
     Diagnostic Confidence Level, mean ± SD 0.38 ± 0.70 N/A N/A 
     UHDRS-TMS, mean ± SD 4.35 ± 7.24 N/A N/A 
     Disease burden score, mean ± SD 305.0 ± 76.8 N/A N/A 
     CAPs, mean ± SD  0.89 ± 0.18 N/A N/A 
     BMI, mean ± SD 26.47 ± 4.5 26.75 ± 5.9 0.417 
     Smoker, n (%) 6 (18.8) 0 (0.0) 0.007* 
     High alcohol consumption, n (%)** 5 (15.6) 6 (20.7) 0.303 
     Psychotropic medication, n (%) 3 (9.4) 5 (17.2) 0.181 
     Monthly METs, mean ± SD 3278.0 ± 6272.5 7481.2 ± 9584.5 0.022* 
     METs (previous day), mean ± SD 168 ± 359.2 85.1 ± 211.8 0.141 
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Group differences were analysed using t-tests for continuous variables and two sample proportion tests for 
categorical variables. Disease burden score was calculated using the formula: age x (CAGn – 35.5). CAPs was 
calculated using the formula: (age x (CAGn - 33.66))/432.3326.  
*Results are significant at p < 0.05  
**High alcohol consumption equates to in excess of 14 alcoholic drinks per week 
HD = Huntington’s disease; CAGn = number of cytosine-adenine-guanine repeats; UHDRS-TMS = Unified 
Huntington’s Disease Rating Scale-Total Motor Score; CAPs = scaled CAG age product score; BMI = body 
mass index; MET= metabolic equivalents; METs (previous day) refers to the METs calculated for the day prior 
to saliva sampling; N/A = not applicable.  
 
Table 2. Cortisol and melatonin values, subjective and objective sleep outcomes and stress, 
anxiety and depression questionnaire scores for premanifest Huntington’s disease and healthy 
control participants. 
 Premanifest HD  Healthy Controls p-value 
Cortisol  nmol/L (mean ± SD) 
Time of awakening (hh:mm) 6:06 ± 1:01 6:21 ± 0:45 0.141 
Time of sample relative to awakening:    
+15 mins 11.08 ± 4.40 11.28 ± 3.32 0.421 
+30 mins 13.84 ± 4.59 13.42 ± 4.29 0.357 
+45 mins 13.69 ± 3.56 13.30 ± 4.41 0.352 
+60 mins 12.26 ± 3.47 11.62 ± 3.72 0.244 
AUCG 38.17 ± 11.30 39.20 ± 10.61 0.357 
Melatonin (pg/mL) 
Reported usual bedtime (hh:mm) 22:05 ± 0:50 22:10 ± 0:31 0.322 
Time of sample relative to bedtime:    
-2 hrs 10.87 ± 7.68 10.02 ± 6.19 0.319 
-1 hr 12.16 ± 7.07 13.71 ± 7.84 0.210 
+0 hrs 17.10 ± 9.30 19.44 ± 11.10 0.187 
+1 hr 19.42 ± 12.02 22.07 ± 11.11 0.188 
AUCG 49.20 ± 25.88 44.41 ± 21.77 0.219 
Actigraphy measures:    
Total time in bed (min) 464.28 ± 46.73 458.58 ± 43.10 0.680 
Total sleep time (min) 403.17 ± 45.20 415.12 ± 40.25 0.365 
Sleep onset latency (min) 7.10 ± 6.80 4.39 ± 3.77 0.106 
Wake after sleep onset (min) 54.02 ± 25.97 39.07 ± 16.87 0.028* 
Number of awakenings 18.47 ± 6.72 14.55 ± 5.33 0.039* 
Average duration of awakenings (min) 2.87 ± 0.64 2.75 ± 0.87 0.625 
Sleep efficiency (%) 86.98 ± 5.42 90.68 ± 3.75 0.012* 
PSQI global score  5.76 ± 3.02 4.97 ± 2.44 0.134 
Epworth Sleepiness Scale Score 4.69 ± 3.61 6.76 ± 3.37 0.025* 
Consensus Sleep Diary:    
Total time in bed (min) 430.42 ± 61.33 434.84 ± 68.48 0.372 
Total sleep time (min) 385.82 ± 53.90 387.92 ± 74.77 0.453 
Sleep onset latency (min) 16.65 ± 19.90 14.35 ± 13.92 0.303 
Wake after sleep onset (min) 19.04 ± 25.37 16.93 ± 22.89 0.412 
Sleep efficiency 90.52 ± 5.17 89.32 ± 9.96 0.487 
Number of awakenings 1.25 ± 1.47 1.75 ± 1.03 0.057 
Average duration of awakenings (min) 10.18 ± 23.46 8.97 ± 11.11  0.059 
Restorative quality of sleep  3.75 ± 0.81 3.80 ± 0.92 0.411 
Perceived Stress Scale 17.12 ± 6.72 19.86 ± 6.85 0.062 
HADS:    
Total score 7.54 ± 5.30 8.38 ± 5.69 0.276 
Anxiety 5.06 ± 3.48 6.00 ± 3.97 0.164 
Depression 2.49 ± 2.52 2.38 ± 2.14 0.427 
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Data are reported as mean and standard deviation, unless stated otherwise. Group differences were analysed 
using t-tests. AUCG was calculated using the trapezoid rule for morning cortisol and evening melatonin output 
using the curve generated from the average cortisol values and the average melatonin values, respectively. Sleep 
efficiency was calculated using the formula: (total sleep time/total time in bed) X 100. PSQI score greater than 5 
indicates poor sleepers. The Consensus Sleep Diary- restorative quality of sleep item is a Likert scale ranging 
from 1 (not restorative) to 5 (very restorative). Higher Perceived Stress Scale scores indicate greater stress. 
HADS sub-scores greater than 7 indicate clinically relevant anxiety and depression symptomatology.  
*Results are significant at p < 0.05.  
HD= Huntington’s disease; AUCG= area under the curve with respect to ground; PSQI= Pittsburgh Sleep 
Quality Index; HADS= Hospital Anxiety and Depression Scale. 
 
Table 3. Association analyses between hypothalamic volume and CAPs, cortisol and 
melatonin 
 Side k Peak voxel 
 t score MNI 
coordinates 
CAPs 
Negative association with CAPs in 
premanifest HD 
B 204 3.16 -3 2 -7 
     
Cortisol 
Negative association with cortisol output 
in premanifest HD 
L 161 2.54 -10 1 -4 
Group by cortisol output interaction L 186 2.32 -10 1 -4 
Melatonin 
Positive association with melatonin output 
in healthy controls 
L 161 2.67 -10 1 -6 
Group by melatonin output interaction L 201 2.41 -6 2 -8 
 
Group differences were analysed using two-sample t-tests. 
*Results are significant at p < 0.05, uncorrected. 
k = No. of voxels; MNI = Montreal Neurological Institute; HD = Huntington’s disease; B = bilateral; L = left. 
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Highlights 
 Circadian rhythm and sleep disturbances are common in Huntington’s disease (HD) 
 Premanifest HD (preHD) individuals show significantly reduced hypothalamic 
volume 
 Hypothalamic pathology has been proposed to mediate circadian and sleep changes 
 Relationships between hypothalamic volume and circadian rhythm differ in preHD 
 No consistent associations exist between the hypothalamus and circadian 
rhythm/sleep 
 
 
